Therefore, we suggest that PUM2-mediated DLX5 regulation may be an important regulatory axis for osteogenic differentiation of human MSCs, and PUM2 could be a target for gene therapy to slow or prevent osteoporosis progression by modulating DLX5-mediated osteogenesis of MSCs. This evidence concerns the gene DLX5 and osteoporosis.